Ahlstrom, "Uptake of Mn[Cl.sub.2] and mangafodipir trisodium in the myocardium: a magnetic resonance imaging study in pigs," Journal of Magnetic Resonance Imaging, vol.
Skotland, "Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood," Journal of Pharmaceutical and Biomedical Analysis, vol.
Skotland, "Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs," European Journal of Drug Metabolism and Pharmacokinetics, vol.
Detection of Liver Metastases from Adenocarcinoma of the Colon and Pancreas: Comparison of Mangafodipir Trisodium
- Enhanced Liver MRI and Whole - Body FDG PET.
One of the earliest HPB agents available was Mangafodipir trisodium
. Mangafodipir trisodium
is a manganese based agent that dissociates rapidly in the blood following slow IV infusion (2 to 3 mL/min over a 10 to 20 min period), releasing freeMn2+ ions.
The older of the 2 agents is mangafodipir trisodium
(TESLASCAN, GE Healthcare, Chalfont St.
The liver-specific contrast agent mangafodipir trisodium
(Teslascan, GE Healthcare, Princeton, NJ) is excreted via the biliary system and T1W MRI after injection of this agent may be useful in the diagnosis of a bile leak.
Hepatocyte-specific contrast agents include mangafodipir trisodium and two gadolinium chelates: Gd-EOBDTPA and Gd-BOPTA.
In addition, in similar fashion to mangafodipir trisodium, these agents also provide excellent biliary ductal detail during the delayed phase.
Like mangafodipir trisodium, this agent also provides a long imaging window after IV infusion, thus facilitating high-spatial-resolution thin-section imaging.